Artane
(trihexyphenidyl)Phase 1Small molecule
This medication helps manage Parkinson's disease symptoms and side effects from certain other drugs by relaxing muscles and reducing nerve signals that control muscle function.[1] Artane is currently being investigated across 2 indications[3], with its most advanced program in Phase 1.[1]
Artane is one of 36 small molecule programs targeting Cerebral Palsy. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
35
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
82 competitors in Cerebral Palsy
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesPhase 3
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Advil
KKenvue Brands
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Cyklokapron
AAmring
Phase 3
Dysport
IpsenPhase 3
Botulinum Toxin
MMeshalkin Research Institute of Pathology of Circulation
Phase 3
Fosamax
Mylan Pharmaceuticals IncPhase 3
PROCRIT
WWim Janssens
Phase 2
Osmitrol
BB. Braun Medical Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
ARTANE
NDA NDA006773
Jan 1, 1982
ARTANE
NDA NDA012947
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for trihexyphenidyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- WWyeth-Lederle Vaccines